Breast Cancer Clinical Trial
Official title:
Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor
This is a single-centre study comprising two phases: a lead-in phase Ib and a phase II
randomized portion.
Lead-in Phase Ib study A lead-in phase I study will be built into this protocol to confirm
the dose of lenvatinib that can safely be combined with letrozole.
We expect that the optimal phase II dose level will be determined after recruiting 12-18
subjects into phase Ib. This dose level will be the one to be tested in the phase II portion
of the study.
Phase II open label study In this part of the study, eligible patients will be treated with
single agent lenvatinib at the phase II recommended dose for 2 weeks, followed by lenvatinib
combined with letrozole 2.5mg daily for 12 weeks.
A total of 30 patients with ER positive breast cancer and measurable primary tumor will be
enrolled over a period of 24-30 months
Hypothesis:
We hypothesize that combining a RET inhibitor such as lenvatinib with endocrine therapy may
potentiate anti-tumor effects in ER+ breast cancers in the clinic. Given that RET inhibition
is the primary mechanism of action of lenvatinib, we further hypothesize that RET expression
in the breast tumor may be a biomarker that predicts for better response to the combination
of a RET inhibitor and endocrine therapy in both a neoadjuvant (Part A) and a metastatic
(Part B) setting.
Primary Objectives
1. To confirm the dose of lenvatinib that can be safely combined with letrozole in the
lead-in Phase Ib part of the study.
2. Part A (For patients with non-metastatic breast cancer undergoing neoadjuvant treatment)
: To determine the overall clinical response (measured by ultrasound) and pathological
complete response rate after 2 weeks of neoadjuvant single agent lenvatinib followed by
12 weeks of letrozole combined with lenvatinib and compare with historical controls
treated with single agent letrozole.
3. Part B (For patients with metastatic breast cancer and who have tumor lesion that can be
serially biopsied safely): to determine the clinical response (measured by RECIST
criteria) after 2 weeks of single agent lenvatinib followed by continuous dual therapy
of lenvatinib and letrozole, until time of progression or intolerability.
Secondary Objectives
1. To evaluate the overall biological effects (Ki67 changes, histological response,
apoptosis, RET and downstream targets such as AKT and ERK) of 2 weeks of single agent
lenvatinib, and of letrozole + lenvatinib, in ER positive breast cancer, respectively.
2. To identify biological predictors for treatment response to letrozole + lenvatinib in ER
positive breast cancer using pharmacokinetics, pharmacogenetics, genomics and proteomics
strategies.
3. To compare the following parameters between RET positive versus RET negative, ER
positive breast cancer:
- Part A :
i. Clinical response (measured by ultrasound) and biological effects of 2 weeks of single
agent lenvatinib, ii. Clinical response (measured by ultrasound) and biological effects after
2 weeks of single agent lenvatinib followed by 12 weeks of letrozole combined with lenvatinib
-Part B : i. Clinical response measured by RECIST criteria after 2 weeks of single agent
lenvatinib followed by letrozole combined with lenvatinib ii. Progression-free and overall
survival with letrozole combined with lenvatinib
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |